KEGG   DRUG: PaliferminHelp
Entry
D05338                      Drug                                   

Name
Palifermin (USAN/INN);
Kepivance (TN)
Product
Formula
C729H1156N204O207S10
Exact mass
16400.3409
Mol weight
16410.8715
Sequence
MSYDYMEGGD IRVRRLFCRT QWYLRIDKRG KVKGTQEMKN NYNIMEIRTV AVGIVAIKGV
ESEFYLAMNK EGKLYAKKEC NEDCNFKELI LENHYNTYAS AKWTHNGGEM FVALNQKGIP
VRGKKTKKEQ KTAHFLPMAI T
  Type
Peptide
Remark
ATC code: V03AF08
Product: D05338<US>
Efficacy
Anti-inflammatory (oral)
Comment
Treatment of mucositis, Keratinocyte growth factor (KGF)
Target
FGFR2 (CD332) [HSA:2263] [KO:K05093]
  Pathway
hsa04550  Signaling pathways regulating pluripotency of stem cells
hsa04810  Regulation of actin cytoskeleton
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 V VARIOUS
  V03 ALL OTHER THERAPEUTIC PRODUCTS
   V03A ALL OTHER THERAPEUTIC PRODUCTS
    V03AF Detoxifying agents for antineoplastic treatment
     V03AF08 Palifermin
      D05338  Palifermin (USAN/INN) <US>
USP drug classification [BR:br08302]
 Dental and Oral Agents
  Palifermin
   D05338  Palifermin (USAN/INN)
Target-based classification of drugs [BR:br08310]
 Protein kinases
  Receptor tyrosine kinases (RTK)
   FGFR family
    FGFR2 (CD332)
     D05338  Palifermin (USAN/INN) <US>
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D05338
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05338
BRITE hierarchy
Other DBs
CAS: 162394-19-6
PubChem: 47207024
DrugBank: DB00039
NIKKAJI: J2.317.269K
LinkDB All DBs

» Japanese version   » Back

DBGET integrated database retrieval system